


This article was downloaded by: [Dr Olubusuyi Moses Adewumi]

On: 20 May 2015, At: 12:54

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



[Click for updates](#)

Journal of Immunoassay and Immunochemistry

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Ijii20>

Efficacy of Generic Highly Active Antiretroviral Therapy in HIV-1 Infected Individuals in Nigeria

Olubusuyi M. Adewumi^a, Georgina N. Odaibo^a & Olufemi D. Olaleye^a

^a Department of Virology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria

Accepted author version posted online: 01 Dec 2014. Published online: 01 Dec 2015.

To cite this article: Olubusuyi M. Adewumi, Georgina N. Odaibo & Olufemi D. Olaleye (2015) Efficacy of Generic Highly Active Antiretroviral Therapy in HIV-1 Infected Individuals in Nigeria, *Journal of Immunoassay and Immunochemistry*, 36:5, 464-477, DOI: [10.1080/15321819.2014.969436](https://doi.org/10.1080/15321819.2014.969436)

To link to this article: <http://dx.doi.org/10.1080/15321819.2014.969436>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms &

UNIVERSITY OF IBADAN LIBRARY

EFFICACY OF GENERIC HIGHLY ACTIVE ANTIRETROVIRAL THERAPY IN HIV-1 INFECTED INDIVIDUALS IN NIGERIA

Olubusuyi M. Adewumi, Georgina N. Odaibo, and Olufemi D. Olaleye

Department of Virology, College of Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria

□ *CD4 T lymphocyte and plasma HIV RNA parameters have been used to monitor disease progression, and predict clinical course in HIV infection. Initial evaluation of these parameters was conducted in the western countries where accessible ARVs, circulating HIV subtypes and mode of transmission are different from the situation in Nigeria. This study appraised these parameters, and efficacy of generic ARVs. Consenting 106 HIV infected ARV naïve patients were enrolled. CD4 T lymphocyte and plasma HIV RNA levels were determined at interval for 24 months. Ninety eight (92.5%) of the patients who completed the follow up in strict adherence to therapy guideline were included in the analysis. Baseline median CD4 T lymphocyte increased from 114 (Range: 6–330) to highest 357 (Range: 15–1036) cells/ μ L at 18 months of therapy, while baseline median plasma viral RNA declined from 4.6 (Range: 2.6–6.0) Log_{10} copies/mL to undetectable level within three months of therapy. Significant CD4 T-cell restoration and plasma viral RNA decline in the study population demonstrate efficacy of the generic HAART. The importance of combined use of both parameters for evaluation of immunologic and virologic responses to ART was confirmed.*

Keywords ART, CD4 T lymphocyte cell, HAART, Nigeria, plasma viral RNA

INTRODUCTION

Human Immunodeficiency Virus (HIV) infects and replicates in CD4 bearing cells including the T lymphocytes thus impairing the immune system. Consequently, CD4 T lymphocyte count is the most commonly used marker for monitoring immune status of infected persons. It is also used for staging the disease, and provision of other essential information for clinical management and monitoring of such individuals.^[1–3] Monitoring of HIV infection was further enhanced with the development of sensitive PCR-based technology to quantify viral RNA levels in the plasma.^[4] Plasma HIV RNA early in HIV infection is highly predictive of clinical course of the

Address correspondence to Olufemi D. Olaleye, Department of Virology, College of Medicine, University of Ibadan, Ibadan, Oyo State 234, Nigeria. E-mail: davidoolaleye@gmail.com

Color versions of one or more of the figures in this article can be found online at www.tandfonline.com/ljii.